DISSEMINATED OVARIAN CANCER: MODERN APPROACH TO DRUG THERAPY (REVIEW OF PUBLISHED LITERATURE)
Abstract
The review presents data on drug therapy for ovarian cancer including neoadjuvant and intraperitoneal chemotherapy. The prospects of using targeted therapy for ovarian cancer are discussed.
About the Authors
S. V. Molchanov
Tomsk Cancer Research Institute
Russian Federation
Russian Federation
Molchanov Sergey Valerievich, MD, PhD, Researcher, Department of Gynecology with the Group of Cancer Prevention.
E-mail: SergeyMolchanov1980@gmail.com. SPIN-code: 2719-3289.
L. A. Kolomiets
Tomsk Cancer Research Institute;
Siberian State Medical University, Tomsk
Russian Federation
Russian Federation
Kolomiets Larisa Alexandrovna, MD, Professor, Honored Scientist ofRussian Federation, Head of Department of Gynecology with the Group of Cancer Prevention, Tomsk Cancer Research Institute.
E-mail: kolomietsla@oncology.tomsk.ru. SPIN-код: 6316-1146.
References
1. Gervas P.A., Litviakov N.V., Popova N.O., Dobrodeev A.Yu., Tarasova A.S., Yumov E.L., Ivanova F.G., Cheremisina O.V., Afanasyev S.G., Goldberg V.E., Cherdyntseva N.V. Problem and perspective to improve molecular testing to choose appropriate target therapy // Sibirskij onkologicheskij zhurnal. 2014. № 2. P. 46–55. [in Russian]
2. Malignant neoplasms in Russia in 2009 (morbidity and mortality) / Eds. V.I. Chissov, V.V. Starinskij, G.V. Petrova. M., 2011. 260 p. [in Russian]
3. Molchanov S.V., Kolomiets L.A. Disseminated ovarian cancer: surgical treatment (Literature review) // Sibirskij onkologicheskij zhurnal. 2014. № 5. P. 54–59. [in Russian]
4. Molchanov S.V., Kolomiyets L.A., Frolova I.G., Vyatkina N.V.1, Baklanova N.S. Peritoneal carcinomatosis in patients with ovarian cancer: echosemiotics and classification // Vestnik RONC im. N. N. Blohina RAMN. 2014. Vol. 25 (1–2). P. 14–20. [in Russian]
5. Tjulandin S.A., Pokataev I.A., Tjulandina A.S., Kuznetsov V.V., Zhordania K.I., Stenina M.B. Treatment of advanced ovarian cancer: results of the department of clinical pharmacology and chemotherapy, N.N. Blokhin PORC in 1999– 2010 // Vestnik Rossijskoj akademii medicinskih nauk. 2011. № 12. P. 4–9. [in Russian]
6. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., Copeland L.J., Walker J.L., Burger R.A. Intraperitoneal cisplatin and paclitaxel in ovarian cancer // N. Engl. J. Med. 2006. Vol. 354 (1). P. 34–43.
7. Bristow R.E., Chi D.S. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a metaanalysis // Gynecol. Oncol. 2006. Vol. 103 (3). P. 1070–1076.
8. Burger R.A., Brady M.F., Rhee J., Sovak M.A., Kong G., Nguyen H.P., Bookman M.A. Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer // Gynecol. Oncol. 2013. Vol. 131 (1). P. 21–26. doi: 10.1016/j.ygyno.2013.07.100.
9. Burger R.A., Sill M.W., Monk B.J., Greer B.E., Sorosky J.I. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study // J. Clin. Oncol. 2007. Vol. 25 (33). P. 5165–5171.
10. Byrne A.T., Ross L., Holash J., Nakanishi M., Hu L., Hofmann J.I., Yancopoulos G.D., Jaffe R.B. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model // Clin. Cancer Res. 2003. Vol. 9 (15). P. 5721–5728.
11. Cannistra S.A., Matulonis U.A., Penson R.T., Hambleton J., Dupont J., Mackey H., Douglas J., Burger R.A., Armstrong D., Wenham R., McGuire W. Phase II study of bevacizumab in patients with platinumresistant ovarian cancer or peritoneal serous cancer // J. Clin. Oncol. 2007. Vol. 25 (33). P. 5180–5186.
12. de Bree E., Tsiftsis D.D. Experimental and pharmacokinetic studies in intraperitoneal chemotherapy: From laboratory bench to bedside // Recent Results Cancer Res. 2007. Vol. 169. P. 53–73.
13. Diaz-Montes T.P., Bristow R.E. Secondary cytoreduction for patients with recurrent ovarian cancer // Curr. Oncol. Rep. 2005. Vol. 7 (6). P. 451–458.
14. Friedlander M., Hancock K.C., Rischin D., Messing M.J., Stringer C.A., Matthys G.M., Ma B., Hodge J.P., Lager J.J. A phase II open-label study evaluating pazopanib in patients with recurrent ovarian cancer // Gynecol. Oncol. 2010. Vol. 119 (1). P. 32–37. doi: 10.1016/j.ygyno.2010.05.033.
15. Fujiwara K., Armstrong D., Morgan M., Markman M. Principles and practice of intraperitoneal chemotherapy for ovarian cancer // Int. J. Gynecol. Cancer. 2007. Vol. 17 (1). P. 1–20.
16. Gelmon K.A., Tischkowitz M., Mackay H., Swenerton K., Robidoux A., Tonkin K., Hirte H., Huntsman D., Clemons M., Gilks B., Yerushalmi R., Macpherson E., Carmichael J., Oza A. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triplenegative breast cancer: a phase 2, multicentre, open-label, non-randomised study // Lancet Oncology. 2011. Vol. 12 (9). P. 852–861. doi: 10.1016/S1470-2045(11)70214-5.
17. Giannopoulos T., Butler-Manuel S., Taylor A., Ngeh N., Thomas H. Clinical outcomes of neoadjuvant chemotherapy and primary debulking surgery in advanced ovarian carcinoma // Eur. J. Gynecol. Oncol. 2006. Vol. 27 (1). P. 25–28.
18. Gori J., Castano R., Toziano M., Häbich D., Staringer J., De Quirós D.G., Felci N. Intraperitoneal hyperthermic chemotherapy in ovarian cancer // Int. J. Gynecol. Cancer. 2005. Vol. 15 (2). P. 233–239.
19. Hainsworth J.D., Numnum T.M., Rao G.G. A randomized phase II study of paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer // J. Clin. Oncol. 2010. Vol. 28. Suppl. 15s. Abs. TPS257.
20. Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings // Mol. Oncol. 2011. Vol. 5 (4). P. 387–393. Doi: 10.1016/j.molonc.2011.07.001.
21. Helm C.W., Richard S.D., Pan J., Bartlett D., Goodman M.D., Hoefer R., Lentz S.S., Levine E.A., Loggie B.W., Metzinger D.S., Miller B., Parker L., Spellman J.E., Sugarbaker P.H., Edwards R.P., Rai S.N. Hyperthermic intraperitoneal chemotherapy in ovarian cancer: first report of the HYPER-O registry // Int. J. Gynecol. Cancer. 2010. Vol. 20 (1). P. 61–69. doi: 10.1111/IGC.0b013e3181c50cde.
22. Hou J.Y., Kelly M.G., Yu H., McAlpine J.N., Azodi M., Rutherford T.J., Schwartz P.E. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease // Gynecol. Oncol. 2007. Vol. 105 (1). P. 211–217.
23. Kang S., Nam B.H. Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies // Ann. Surg. Oncol. 2009. Vol. 16 (8). P. 2315–2320. doi: 10.1245/s10434-009-0558-6.
24. Kumar L., Hariprasad R., Kumar S. et al. Neoadjuvant chemotherapy in advanced epithelial ovarian oancer (EOC): a Phase III randomized study // J. Clin. Oncol. (Meeting Abstracts). 2006. Vol. 24. Suppl. 18. Abs. 15000.
25. Ledermann J.A., Harter P., Gourley C., Friedlander M., Vergote I., Rustin G., Scott C., Meier W., Shapira-Frommer R., Safra T., Matei D., Macpherson E., Watkins C., Carmichael J., Matulonis U. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer // N. Engl. J. Med. 2012. Vol. 366 (15). P. 1382–1392. doi: 10.1056/NEJMoa1105535.
26. Ledermann J.A., Rustin G.J., Hackshaw A. et al. A randomized phase II placebo controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer // J. Clin. Oncol. 2009. Vol. 27. Suppl. 15s. Abs. 5501.
27. Matulonis U.A., Berlin S., Ivy P., Tyburski K., Krasner C., Zarwan C., Berkenblit A., Campos S., Horowitz N., Cannistra S.A., Lee H., Lee J., Roche M., Hill M., Whalen C., Sullivan L., Tran C., Humphreys B.D., Penson R.T. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer // J. Clin. Oncol. 2009. Vol. 27 (33). P. 5601–5606. doi: 10.1200/JCO.2009.23.2777.
28. Menczer J., Usviatzov I., Ben-Shem E., Golan A., Levy T. Neoadjuvant chemotherapy in ovarian, primary peritoneal and tubal carcinoma: can imaging results prior to interval debulking predict survival? // J. Gynecol. Oncol. 2011. Vol. 22 (3). P. 183–187. doi: 10.3802/jgo.2011.22.3.183.
29. Micha J.P., Goldstein B.H., Rettenmaier M.A., Genesen M., Graham C., Bader K., Lopez K.L., Nickle M., Brown J.V. 3rd. A phase II study of outpatient fi rst-line paclitaxel, carboplatin, and bevacizumab for advancedstage epithelial ovarian, peritoneal, and fallopian tube cancer // Int. J. Gynecol. Cancer. 2007. Vol. 17 (4). P. 771–776.
30. Miyagi Y., Fujiwara K., Kigawa J., Itamochi H., Nagao S., Aotani E., Terakawa N., Kohno I. Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy: a comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs intravenous infusion of carboplatin – a Sankai Gynecology Study Group (SGSG) study // Gynecol. Oncol. 2005. Vol. 99 (3). P. 591–596.
31. Onda T., Yoshikawa H. Neoadjuvant chemotherapy for advanced ovarian cancer: overview of outcomes and unanswered questions // Exp. Rev. Anticancer Ther. 2011. Vol. 11 (7). P. 1053–1067. doi: 10.1586/era.11.24.
32. Parson E.N., Lentz S., Russell G., Shen P., Levine E.A., Stewart J.H. 4th. Outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface dissemination from ovarian neoplasms // Am. J. Surg. 2011. Vol. 202 (4). P. 481–486. doi: 10.1016/j.amjsurg.2011.02.004.
33. Perren T., Swart A.M., Pfisterer J. et al. ICON7: A phase III randomized gynecologic cancer intergroup trial of concurrent bevacizumab and chemotherapy followed by maintenance bevecizumab versus chemotherapy alone in women with new diagnosed epithelial ovarian, primary peritoneal or fallopian tube cancer // Ann. Oncol. 2010. Vol. 21. Suppl. 8. P. LBA4.
34. Rose P.G., Drake R., Braly P.S. et al. Preliminary results of a phase II study of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube // J. Clin. Oncol. ASCO Annual Meeting. 2009. Vol. 27. Abs. 5546.
35. Roviello F., Pinto E., Corso G., Pedrazzani C., Caruso S., Filippeschi M., Petrioli R., Marsili S., Mazzei M.A., Marrelli D. Safety and potential benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal carcinomatosis from primary or recurrent ovarian cancer // J. Surg. Oncol. 2010. Vol. 102 (6). P. 663–670. doi: 10.1002/jso.21682.
36. Rufián S., Muñoz-Casares F.C., Briceño J., Díaz C.J., Rubio M.J., Ortega R., Ciria R., Morillo M., Aranda E., Muntané J., Pera C. Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer // J. Surg. Oncol. 2006. Vol. 94 (4). P. 316–324.
37. Ryu K.S., Kim J.H., Ko H.S., Kim J.W., Ahn W.S., Park Y.G., Kim S.J., Lee J.M. Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer // Gynecol. Oncol. 2004. Vol. 94 (2). P. 325–332.
38. Santillan A., Karam A. K., Li A.J., Giuntoli R. 2nd, Gardner G.J., Cass I. Karlan B.Y., Bristow R.E. Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer // Gynecol. Oncol. 2007. Vol. 104 (3). P. 686–690.
39. Shen G.H., Ghazizadeh M., Kawanami O., Shimizu H., Jin E., Araki T., Sugisaki Y. Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma // Br. J. Cancer. 2000. Vol. 83 (2). P. 196–203.
40. Steed H., Oza A.M., Murphy J., Laframboise S., Lockwood G., Petrillo D.E., Sturgeon J., Rosen B. A retrospective analysis of neoadjuvant platinum-based chemotherapy versus up-front surgery in advanced ovarian cancer // Int. J. Gynecol. Cancer. 2006. Vol. 16. Suppl. 1. P. 47–53.
41. Sticca R.P., Dach B.W. Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents // Surg. Oncol. Clin. N. Am. 2003. Vol. 12 (3). P. 689–701.
42. Takemoto M., Kuroda M., Urano M., Nishimura Y., Kawasaki S., Kato H., Okumura Y., Akaki S., Kanazawa S., Asaumi J., Joja I., Hiraki Y. The effect of various chemotherapeutic agents given at mild hyperthermia on different types of tumors // Int. J. Hyperthermia. 2003. Vol. 19 (2). P. 193–203.
43. Trimble E.L., Christian M.C. National Cancer Institute – United States strategy regarding intraperitoneal chemotherapy for ovarian cancer // Int. J. Gynecol. Cancer. 2008. Vol. 18. Suppl. 1. P. 26–28. doi: 10.1111/j.1525-1438.2007.01100.x.
44. Vasey P.A., Jayson G.C., Gordon A., Gabra H., Coleman R., Atkinson R., Parkin D., Paul J., Hay A., Kaye S.B. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma // J. Natl. Cancer Inst. 2004. Vol. 96 (22). P. 1682–1691.
45. Vergote I., Tropé C.G., Amant F., Kristensen G.B., Ehlen T., Johnson N., Verheijen R.H., van der Burg M.E., Lacave A.J., Panici P.B., Kenter G.G., Casado A., Mendiola C., Coens C., Verleye L., Stuart G.C., Pecorelli S., Reed N.S. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer // N. Engl. J. Med. 2010. Vol. 363 (10). P. 943–953. doi: 10.1056/NEJMoa0908806.
46. Walker J.L., Armstrong D.K., Huang H.Q., Fowler J., Webster K., Burger R.A., Clarke-Pearson D. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study // Gynecol. Oncol. 2006. Vol. 100 (1). P. 27–32.
47. Weinberg L.E., Rodriguez G., Hurteau J.A. The role of neoadjuvant chemotherapy in treating advanced epithelial ovarian cancer // J. Surg. Oncol. 2010. Vol. 101 (4). P. 334–343. doi: 10.1002/jso.21482.
Review
For citations:
Molchanov S.V., Kolomiets L.A. DISSEMINATED OVARIAN CANCER: MODERN APPROACH TO DRUG THERAPY (REVIEW OF PUBLISHED LITERATURE). Siberian journal of oncology. 2015;(6):68-75. (In Russ.)
Views:
660
Email this article 
